STRO
Income statement / Annual
Last year (2024), Sutro Biopharma, Inc.'s total revenue was $62.04 M,
a decrease of 59.64% from the previous year.
In 2024, Sutro Biopharma, Inc.'s net income was -$227.46 M.
See Sutro Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$62.04 M |
$153.73 M |
$67.77 M |
$61.88 M |
$42.72 M |
$42.74 M |
$38.42 M |
$51.74 M |
$59.73 M |
| Cost of Revenue |
$7.22 M
|
$6.82 M
|
$8.29 M
|
$9.77 M
|
$76.96 M
|
$0.00
|
$54.26 M
|
$51.90 M
|
$43.55 M
|
| Gross Profit |
$54.83 M
|
$146.92 M
|
$59.48 M
|
$52.11 M
|
-$34.24 M
|
$42.74 M
|
-$15.84 M
|
-$156.00 K
|
$16.18 M
|
| Gross Profit Ratio |
0.88
|
0.96
|
0.88
|
0.84
|
-0.8
|
1
|
-0.41
|
-0
|
0.27
|
| Research and Development Expenses |
$252.04 M
|
$180.43 M
|
$137.17 M
|
$104.40 M
|
$76.96 M
|
$65.61 M
|
$54.26 M
|
$54.64 M
|
$43.55 M
|
| General & Administrative Expenses |
$48.45 M
|
$62.58 M
|
$59.54 M
|
$56.00 M
|
$36.82 M
|
$32.59 M
|
$21.38 M
|
$16.37 M
|
$14.82 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$48.45 M
|
$62.58 M
|
$59.54 M
|
$56.00 M
|
$36.82 M
|
$32.59 M
|
$21.38 M
|
$16.37 M
|
$14.82 M
|
| Other Expenses |
-$7.22 M
|
-$6.82 M
|
-$8.29 M
|
-$9.77 M
|
-$76.96 M
|
$0.00
|
$1.91 M
|
-$77.00 K
|
$87.00 K
|
| Operating Expenses |
$293.28 M
|
$236.19 M
|
$188.43 M
|
$150.63 M
|
$36.82 M
|
$98.20 M
|
$75.64 M
|
$71.01 M
|
$58.37 M
|
| Cost And Expenses |
$300.50 M
|
$243.01 M
|
$196.72 M
|
$160.40 M
|
$113.78 M
|
$98.20 M
|
$75.64 M
|
$71.01 M
|
$58.37 M
|
| Interest Income |
$44.43 M
|
$14.51 M
|
$3.46 M
|
$577.00 K
|
$1.51 M
|
$4.07 M
|
$1.62 M
|
$273.00 K
|
$251.00 K
|
| Interest Expense |
$31.07 M
|
$23.75 M
|
$3.35 M
|
$3.14 M
|
$3.97 M
|
$4.35 M
|
$1.60 M
|
$689.00 K
|
$0.00
|
| Depreciation & Amortization |
$7.22 M
|
$6.82 M
|
$8.29 M
|
$4.84 M
|
$4.30 M
|
$4.78 M
|
$4.54 M
|
$4.99 M
|
$5.66 M
|
| EBITDA |
-$180.45 M |
-$67.92 M |
-$105.07 M |
-$97.56 M |
-$23.75 M |
-$46.62 M |
-$32.82 M |
-$14.09 M |
$7.36 M |
| EBITDA Ratio |
-2.91
|
-0.44
|
-1.55
|
-1.58
|
-0.56
|
-1.09
|
-0.85
|
-0.27
|
0.12
|
| Operating Income Ratio |
-3.84
|
-0.58
|
-1.9
|
-1.59
|
-1.66
|
-1.3
|
-0.97
|
-0.37
|
0.02
|
| Total Other Income/Expenses Net |
$13.36 M
|
$677.00 K
|
$12.24 M
|
-$7.01 M
|
$38.93 M
|
-$276.00 K
|
$1.91 M
|
-$416.00 K
|
$338.00 K
|
| Income Before Tax |
-$225.10 M
|
-$88.60 M
|
-$116.70 M
|
-$105.54 M
|
-$32.13 M
|
-$55.74 M
|
-$35.32 M
|
-$19.69 M
|
$1.70 M
|
| Income Before Tax Ratio |
-3.63
|
-0.58
|
-1.72
|
-1.71
|
-0.75
|
-1.3
|
-0.92
|
-0.38
|
0.03
|
| Income Tax Expense |
$2.36 M
|
$18.19 M
|
$2.50 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$227.46 M
|
-$106.79 M
|
-$119.20 M
|
-$105.54 M
|
-$32.13 M
|
-$55.74 M
|
-$35.32 M
|
-$19.69 M
|
$1.70 M
|
| Net Income Ratio |
-3.67
|
-0.69
|
-1.76
|
-1.71
|
-0.75
|
-1.3
|
-0.92
|
-0.38
|
0.03
|
| EPS |
-29.6 |
-17.8 |
-23.5 |
-22.9 |
-9.9 |
-24.3 |
-15.5 |
-28.1 |
38.6 |
| EPS Diluted |
-29.6 |
-17.8 |
-23.5 |
-22.9 |
-9.9 |
-24.3 |
-15.4 |
-28.1 |
38.6 |
| Weighted Average Shares Out |
$7.68 M
|
$6.02 M
|
$5.07 M
|
$4.61 M
|
$3.26 M
|
$2.30 M
|
$2.29 M
|
$699.74 K
|
$44.12 K
|
| Weighted Average Shares Out Diluted |
$7.68 M
|
$6.02 M
|
$5.07 M
|
$4.61 M
|
$3.26 M
|
$2.30 M
|
$2.29 M
|
$699.74 K
|
$44.12 K
|
| Link |
|
|
|
|
|
|
|
|
|
